Cellular immunotherapy for acute myeloid leukemia: from bench to bedside.
- 1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei P.R. China.
- 2Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan P.R. China.
Abstract
Acute myeloid leukemia (AML) is a clonal malignant disease that arises from hematopoietic stem cells and is characterized by high genetic heterogeneity. AML has a poor prognosis, with a low 5-year survival rate, and is typically treated with chemotherapy. The management of AML, particularly for cases that are relapsed or refractory to conventional chemotherapy and transplantation, remains a formidable clinical challenge. This comprehensive review systematically evaluates the current landscape of cellular immunotherapeutic strategies for AML. We focus on the mechanisms of action, recent clinical progress, and persistent challenges associated with a range of adoptive cell therapies. These include natural killer cell-based infusions, and engineered approaches such as chimeric antigen receptor-T, CAR-NK, and CAR-macrophage therapies. Furthermore, we examine the roles of tumor-infiltrating lymphocytes and cytokine-induced killer cells. Our analysis synthesizes evidence from preclinical studies and clinical trials to assess the potential of these modalities in inducing durable antileukemic responses. We conclude that while cellular immunotherapies represent a transformative frontier in AML treatment, their broad application is currently constrained by target antigen heterogeneity, a complex tumor microenvironment, and significant toxicities. Finally, this review discusses strategic innovations necessary to overcome these barriers, highlighting directions for future research aimed at enhancing the efficacy and safety of these promising treatments for AML patients.
Related
- Biologically Informed Multi-Omics Integration Reveals Clinically Meaningful Patient Representations in Acute Myeloid Leukemia
- Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia
- CSE1L enrichment in pediatric and young adult acute myeloid leukemia reveals a ribosomal export dependency
- Integrated multi-omics reveals methylation-linked biological heterogeneity in intermediate-risk pediatric acute myeloid leukemia
- Single-cell dissection of self-derived versus donor-derived T cell exhaustion niches in patients with acute myeloid leukemia
BibTeX
@article{wang2026cellular,
title = {{Cellular immunotherapy for acute myeloid leukemia: from bench to bedside.}},
author = {Yu Wang and Jiaying Wu and Xiaobing Huang and Yi Xiao},
journal = {Immunotherapy advances},
year = {2026},
month = jul,
doi = {10.1093/immadv/ltag012},
url = {https://europepmc.org/article/MED/42909897},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cellular immunotherapy for acute myeloid leukemia: from bench to bedside.
AU - Yu Wang
AU - Jiaying Wu
AU - Xiaobing Huang
AU - Yi Xiao
PY - 2026
DA - 2026/07/08
JO - Immunotherapy advances
DO - 10.1093/immadv/ltag012
UR - https://europepmc.org/article/MED/42909897
AB - Acute myeloid leukemia (AML) is a clonal malignant disease that arises from hematopoietic stem cells and is characterized by high genetic heterogeneity. AML has a poor prognosis, with a low 5-year survival rate, and is typically treated with chemotherapy. The management of AML, particularly for cases that are relapsed or refractory to conventional chemotherapy and transplantation, remains a formidable clinical challenge. This comprehensive review systematically evaluates the current landscape of cellular immunotherapeutic strategies for AML. We focus on the mechanisms of action, recent clinical progress, and persistent challenges associated with a range of adoptive cell therapies. These include natural killer cell-based infusions, and engineered approaches such as chimeric antigen receptor-T, CAR-NK, and CAR-macrophage therapies. Furthermore, we examine the roles of tumor-infiltrating lymphocytes and cytokine-induced killer cells. Our analysis synthesizes evidence from preclinical studies and clinical trials to assess the potential of these modalities in inducing durable antileukemic responses. We conclude that while cellular immunotherapies represent a transformative frontier in AML treatment, their broad application is currently constrained by target antigen heterogeneity, a complex tumor microenvironment, and significant toxicities. Finally, this review discusses strategic innovations necessary to overcome these barriers, highlighting directions for future research aimed at enhancing the efficacy and safety of these promising treatments for AML patients.
SN - 2732-4303
ER -